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13; revised manuscript received May 13, 2013,dabigatran 150 mg bid and the noninferiority of 110 mg bid
compared with warfarin for prevention of stroke or systemic
embolism. Both doses of dabigatran signiﬁcantly reduced
hemorrhagic stroke (1,2). The higher dose of dabigatran
reduced ischemic stroke and cardiovascular mortality, whereas
the lower dose caused less major bleeding. There was no
signiﬁcant difference in cardiovascular and all-cause mortality
between the 2 doses of dabigatran.
In the absence of a signiﬁcant difference between the 2
dabigatran doses on mortality, how to compare the inte-
grated effects of the 2 doses of dabigatran on all events is not
clear. One approach is to examine the effects of the 2 doses
in patient subgroups. For example, the effects of dabigatran
on the primary outcome of stroke or systemic embolism
were consistent across subgroups, but the higher dose of
dabigatran was associated with a higher rate of extracranial
bleeding in the elderly (3). Balanced against this, however,
Abbreviations
and Acronyms
AF = atrial ﬁbrillation
CI = conﬁdence interval
CNS = central nervous
system
FDA = Food and Drug
Administration
MI = myocardial infarction
TIA = transient ischemic
attack
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901older patients have a signiﬁcantly higher risk of stroke than
younger patients, indicating a larger absolute beneﬁt of the
higher dose for prevention of ischemic stroke in older
patients.
The different effects of the 2 doses of dabigatran on stroke
and bleeding have led to conﬂicting recommendations by
regulators. The European Medicines Agency, Health
Canada, and the Australian Therapeutic Goods Adminis-
tration approved both doses of dabigatran and recom-
mended the lower dose for elderly patients. The U.S. Food
and Drug Administration (FDA) approved the 150 mg bid
dose but not 110 mg bid, based on their assessment that
“nonfatal and extracranial bleeding episodes are clearly less
clinically signiﬁcant than strokes for most patients“ and that
they were “unable to ﬁnd any population for whom the
availability of a lower dose would improve dabigatran’s
beneﬁt–risk proﬁle” (4). The U.S. FDA also approved the
75 mg bid dose for the treatment of patients with estimated
glomerular ﬁltration rate 15 to 29 ml/min, although this was
based on pharmacokinetic modeling as the 75 mg dose was
not tested in the RE-LY trial. The apparent disparity in the
decisions of these public agencies has caused considerable
uncertainly for clinicians and further highlights the need for
methods to integrate the anti-ischemic and hemorrhagic
effects of antithrombotic therapy by means of a validated
measure of net clinical beneﬁt.
Currently no concept of assessing net clinical beneﬁt has
been generally accepted. Simply adding up the number of
deaths, ischemic strokes, hemorrhagic strokes, myocardial
infarctions and major bleeding events could yield misleading
results because the relative importance of thrombotic and
bleeding events for patients (in terms of mortality, disability,
and costs) is not equivalent. A more useful approach to
assess the net clinical beneﬁt of dabigatran and warfarin
might be to integrate the overall effects of the drugs
including all important clinical events with weighting of
events according to their measured clinical importance.
In this report we explore whether the use of a weighted
net beneﬁt assessment, ﬁrst reported in the ACTIVE
(Atrial Fibrillation Clopidogrel Trial With Irbesartan for
Prevention of Vascular Events) trial (5) and further devel-
oped here, could improve our understanding of the net
beneﬁt of each dose of dabigatran and warfarin in the
RE-LY trial.Methods
The RE-LY trial. The RE-LY trial design has been
previously published (6). Brieﬂy, the primary study objective
was to establish the non-inferiority of each of 2 doses of
dabigatran compared with warfarin for stroke prevention in
patients with AF. The RE-LY investigators randomized
18,113 patients with AF, who had at least 1 additional risk
factor for stroke, to receive dabigatran 110 mg bid, dabi-
gatran 150 mg bid, or dose-adjusted warfarin (target inter-
national normalized ratio 2.0 to 3.0) for a median of 2 years.The main efﬁcacy outcome was
stroke or systemic embolism and
the main safety outcome was
major bleeding. Major efﬁcacy
and safety outcomes were
deﬁned using objective criteria,
as previously described in the
RE-LY methods paper (6).
Weighting of events according
to their impact on death. We
generated weights for each
outcome (ischemic stroke, non–
central nervous system [CNS] systemic embolism, hemor-
rhagic stroke, subdural bleeding, major extracranial bleeding
[major bleeding excluding extracranial bleeding], and
myocardial infarction [MI]) in the RE-LY trial database
using the methods previously published (5). For the ﬁrst
occurrence of each ischemic and bleeding event, the hazard
ratio for death after the event was estimated using a Cox
regression model adjusted for all important baseline predic-
tors of death, and including the outcome as a time-dependent
covariate. Both unadjusted and adjusted models were
explored but yielded similar results and we therefore present
only adjusted analyses. Pre-speciﬁed variables included in the
adjusted models were age, sex, history of stroke or transient
ischemic attack (TIA), hypertension, heart failure, diabetes,
and MI or coronary artery disease. Randomized treatment
was included as a stratiﬁcation variable. Weights for each
event represent the ratio of the adjusted hazard ratios for that
event, using the hazard ratio for ischemic stroke as
a reference.
We combined the data from the ACTIVE and RE-LY
trials in order to increase the number of each type of event
and thereby to obtain themost precise estimates of the relative
prognostic impact (i.e., weights) of different events. We ﬁrst
assessed whether the weights that we previously computed
from patients with AF receiving antiplatelet therapy (in
ACTIVE-warfarin [7] and ACTIVE-aspirin [8]) differed
from those computed from patients receiving anticoagulant
therapy (inRE-LY [1,2] andACTIVE-warfarin [7]).Having
shown that the weights calculated in these 2 patient pop-
ulations were not statistically different, we then calculated the
impact of each type of event on mortality using the combined
data from the ACTIVE and RE-LY trial databases.
Calculation of net clinical beneﬁt. We ﬁrst calculated the
crude incidence rate (IR) per 100 patient years for the ﬁrst
occurrence of each outcome for patients receiving dabigatran
110 mg bid, dabigatran 150 mg bid, and warfarin. Net
clinical beneﬁt was deﬁned as the weighted sum of these
rates in the experimental group minus the weighted sum of
these rates in the comparator group according to the fol-
lowing formula: net clinical beneﬁt ¼ [IR ischemic_treatment 1 þ
w1 IR non-CNS embolism_treatment 1þ w2 IR hemorrhagic_treatment 1þ
w3 IR subdural_treatment 1 þ w4 IR extracranial_treatment 1 þ w5
IR MI_treatment 1] – [IR ischemic_treatment 2 þ w1 IR non-CNS
embolism_treatment 2 þ w2 IR hemorrhagic_treatment 2 þ w3
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902IR subdural_treatment 2 þ w4 IR extracranial_treatment 2 þ w5 IR
MI treatment 2] in which w1, w2, w3, w4, and w5 are the
weights associated with non-CNS systemic embolism,
hemorrhagic stroke, subdural bleeding, major extracranial
bleeding, and MI, respectively.
We expressed net clinical beneﬁt as ischemic stroke
equivalents prevented per 100 patient years of treatment
because ischemic stroke was used as the reference outcome
for each weight. Estimates of net clinical beneﬁt were
calculated for the overall trial population and for subgroups
categorized by age <75 or 75 years; the presence or
absence of history of heart failure, diabetes and stroke/TIA;
CHADS2 score of <3 or 3 (calculated by assigning 1
point for each of congestive heart failure, hypertension, age
>75 years, and diabetes; and 2 points for history of stroke)
(9); CHA2DS2VASc score of 0 to 1, 2 to 4, or 5
(calculated by assigning 1 point for each of congestive heart
failure, hypertension, diabetes, history of vascular disease,
age 65 to 74 years, and female sex; and 2 points for age >75
years and history of stroke) and HAS-BLED score (calcu-
lated by assigning 1 point for each of blood pressure >160
mm Hg, abnormal renal function, abnormal liver function,
history of stroke, history of bleeding, labile international
normalized ratio, age >65 years, concomitant use of anti-
platelet or nonsteroidal anti-inﬂammatory drugs, and
alcohol abuse) (9); baseline systolic blood pressure above
or below the median level; and creatinine clearance <50
or 50 ml/min as estimated by the Cockcroft-Gault
formula (10).
We obtained conﬁdence intervals for net clinical beneﬁt
by using the bias corrected and accelerated bootstrap
method. One thousand bootstrap samples were obtained and
stratiﬁed by treatment, and the incidence rate, weightings
and net clinical beneﬁt were estimated from each. We then
used a Z test or analysis of variance to compare the net
clinical beneﬁt of the treatments and to obtain a p value.
Sensitivity analyses. We explored the robustness of our
results by examining the effects of dabigatran 110 mg bid,
dabigatran 150 mg bid, and warfarin on net clinical beneﬁt
expressed as death equivalents, in which we weighted
hemorrhagic stroke as being equivalent to 0.25, 0.5, or 0.75
deaths. All other events were then weighted relative to
hemorrhagic stroke using previously calculated weights. For
this analysis, net clinical beneﬁt was deﬁned as the weighted
sum of these rates in the experimental group minus the
weighted sum of these rates in the comparator group, in the
same way as described previously, except that we gave
patients who died a score of 1 and we gave those who did
not die a score that represents the sum of nonfatal events
expressed as death equivalents.
In secondary analyses we also explored the effects of dabi-
gatran 110 mg bid, dabigatran 150 mg bid, and warfarin
on various composites of serious thrombotic and bleeding
events, including stroke or major bleeding, disabling stroke or
life-threatening bleeding, disabling stroke or life-threatening
bleeding or death, disabling stroke or life-threatening
Figure 1
Weighted Net Clinical Beneﬁt of Dabigatran 110 mg bid Compared With Warfarin, Dabigatran 150 mg bid Compared
With Warfarin, and Dabigatran 150 mg bid Compared With Dabigatran 110 mg bid
Results are expressed as ischemic stroke equivalents. CI ¼ conﬁdence interval.
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903bleeding or cardiovascular death, stroke or myocardial
infarction or major bleeding, and stroke or systemic embolism
or myocardial infarction or pulmonary embolism or death or
major bleeding (unweighted net clinical beneﬁt).
We used SAS version 9.1 (SAS Institute, Cary, North
Carolina) for all analyses.
Results
The most common clinical events, which occurred in patients
in the RE-LY trial were deaths (1,371 events), extracrani-
al major bleeding (956 patients with at least 1 event),Table 2
Weighted Net Clinical Beneﬁt of Dabigatran 110 mg bid Com
Warfarin, and Dabigatran 150 mg bid Compared With Dabig
Net Clinic
Dabigatran 110 mg bid versus warfarin
(n ¼ 12,037)
Ischemic stroke equivalents 0
Death equivalents*
Hemorrhagic stroke ¼ 0.25 deaths 0
Hemorrhagic stroke ¼ 0.50 deaths 0
Hemorrhagic stroke ¼ 0.75 deaths 0
Dabigatran 150 mg bid versus warfarin
(n ¼ 12,098)
Ischemic stroke equivalents 1
Death equivalents*
Hemorrhagic stroke ¼ 0.25 deaths 0
Hemorrhagic stroke ¼ 0.50 deaths 0
Hemorrhagic stroke ¼ 0.75 deaths 0
Dabigatran 150 mg bid versus dabigatran 110 mg bid
(n ¼ 12,091)
Ischemic stroke equivalents 0
Death equivalents*
Hemorrhagic stroke ¼ 0.25 deaths 0
Hemorrhagic stroke ¼ 0.50 deaths 0
Hemorrhagic stroke ¼ 0.75 deaths 0
*In these analyses hemorrhagic stroke was assigned a weight of 0.25, 0.5, or 0.75 deaths. All othe
Weights were used to calculate net clinical beneﬁt according to the formula: net clinical beneﬁt ¼ [incid
w3 IR subdural_treatment 1 þ w4 IR extracranial_treatment 1 þ w5 IR MI_treatment 1] – [IR ischemic_treatment 2 þ
IR extracranial_treatment 2 þ w5 IR MI treatment 2], in which IR is per 100 patient years of each outcome for patie
w5 are the weights associated with non-–central nervous system systemic embolism, hemorrhagic strok
CI ¼ conﬁdence interval.and ischemic strokes (413 patients with at least 1 event).
MI (clinical and silent; 270 patients with at least 1
event), systemic embolism (35 patients with at least 1 event),
hemorrhagic stroke (71 patients with at least 1 event), and
subdural bleeding (79 patients with at least 1 event) were less
common.
Weighting of thrombotic and bleeding events. Table 1
shows the number of ischemic strokes, non-CNS systemic
emboli, hemorrhagic strokes, subdural bleeds, extracranial
major bleeds, and MIs; the number of deaths that occurred
in these patients, and the adjusted hazard ratio for death
following each of these outcomes for patients on oralpared With Warfarin, Dabigatran 150 mg Compared With
atran 110 mg bid
al Beneﬁt 95% CI p Value
.92 1.74 to 0.21 0.02
.41 0.92 to 0.08 0.12
.44 0.96 to 0.05 0.10
.48 1.00 to 0.02 0.07
.08 1.86 to 0.34 0.01
.54 1.07 to 0.05 0.03
.59 1.12 to 0.09 0.02
.64 1.17 to 0.14 0.01
.16 0.80 to 0.43 0.60
.13 0.62 to 0.34 0.60
.15 0.64 to 0.32 0.55
.16 0.66 to 0.30 0.53
r events were then weighted relative to hemorrhagic stroke using previously calculated weights.
ence ratio (IR) ischemic_treatment 1 þ w1 IR non-CNS embolism_treatment 1 þ w2 IR hemorrhagic_treatment 1 þ
w1 IR non-CNS embolism_treatment 2 þ w2 IR hemorrhagic_treatment 2 þ w3 IR subdural_treatment 2 þ w4
nts receiving dabigatran 110 mg bid, dabigatran 150 mg bid, and warfarin and w1, w2, w3, w4, and
e, subdural bleeding, major extracranial bleeding, and myocardial infarction, respectively.
Figure 2 Weighted Net Clinical Beneﬁt in Subgroups
(A) Dabigatran 110 mg bid compared with warfarin, (B) dabigatran 150 mg compared with warfarin, and (C) dabigatran 150 mg bid compared with dabigatran 110 mg bid.
Results are expressed as ischemic stroke equivalents. CAD ¼ coronary artery disease; CI ¼ conﬁdence interval; MI ¼ myocardial infarction; SBP ¼ systolic blood pressure;
TIA ¼ transient ischemic attack
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904anticoagulant therapy (from both the RE-LY and ACTIVE
trials), on antiplatelet therapy (from ACTIVE) and for all
patients (from both the RE-LY and ACTIVE trials).
Although there were differences in the hazard ratio for
death, there were no signiﬁcant differences in the relative
weights for death after a speciﬁc event in patients receiving
antiplatelet therapy or receiving anticoagulant therapy.
Therefore, the weights derived from the entire dataset
provide the most precise estimates of the relative importance
of each event. The adjusted hazard ratio for death after
hemorrhagic stroke was 26.92 (95% conﬁdence interval
[CI]: 21.08 to 34.39) whereas that for ischemic stroke was
8.33 (95% CI: 7.09 to 9.79). Therefore, a hemorrhagicstroke increased the hazard ratio for death by 3.29-fold
compared with the increase in risk of death after an ischemic
stroke. The adjusted hazard ratio for non-CNS systemic
embolism was 0.90 compared with an ischemic stroke;
the corresponding numbers for subdural hemorrhage, major
extracranial bleeding and myocardial infarction were 0.79,
0.71, and 0.96, respectively (Table 1).
Weighted beneﬁt as ischemic stroke equivalents. Both
doses of dabigatran resulted in a signiﬁcant reduction
in ischemic stroke equivalents, compared with warfarin
(Fig. 1, Table 2). With dabigatran 110 mg bid the
reduction in ischemic stroke equivalents per 100 patient
years was –0.92 (95% CI –1.74 to 0.21, p ¼ 0.02); and
Figure 2 Continued
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905with dabigatran 150 mg bid the reduction was –1.08 (95%
CI –1.86 to 0.34, p ¼ 0.01). These results were
consistent in all subgroups examined (Figs. 2A and 2B,
Online Table 1).
There was no signiﬁcant difference in ischemic stroke
equivalents of dabigatran 150 mg bid compared with dabiga-
tran 110 mg bid (Fig. 1, Table 2); a difference of –0.16
ischemic stroke equivalents with dabigatran 150 mg bid (95%
CI: –0.80 to 0.43). Exploratory subgroup analyses provided no
evidence of any difference in ischemic stroke equivalents for
either dose of dabigatran according to age, heart failure, dia-
betes, prior stroke/TIA, categories of HAS-BLED score,
systolic blood pressure above and below themedian, creatinine
clearance<50 versus50ml/min, or history of coronary artery
disease/MI. There was a nominally signiﬁcant interaction
between categories of CHADS2 score (p ¼ 0.03) anddabigatran dose; the lower compared with higher dose of
dabigatran appeared to be associated with increased beneﬁt in
patients with a CHADS2 score of 3, whereas the higher
compared with lower dose of dabigatran appeared to be asso-
ciated with increased beneﬁt in patients with a CHADS2 score
of <3 (Fig. 2C, Online Table 2). A similar interaction was
evident for CHA2DS2VASc score of 0 to 1, 2 to 4, or5 (p¼
0.01).
Sensitivity analyses. The net clinical beneﬁt of dabigatran
150 mg bid compared with 110 mg bid was similar when we
included deaths in the weighted beneﬁt analysis irrespective
of whether we weighted hemorrhagic stroke as being
equivalent to 0.25, 0.5, or 0.75 deaths (Table 2).
The effects of dabigatran 110 mg bid, dabigatran 150 mg
bid, and warfarin on various composites of serious thrombotic
and bleeding events were consistent with the results of the
Figure 2 Continued
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906primary weighted net clinical beneﬁt analyses as well as with
the previously reported unweighted net clinical beneﬁt (1),
a composite outcome that included stroke, systemic embolism,
MI, pulmonary embolism, death, or major bleeding (Table 3).
Thus, there was no signiﬁcant difference between dabigatran
150 mg bid and dabigatran 110 mg bid in their effects on
various composites of serious thrombotic and bleeding events.
Discussion
The analysis integrating the information on efﬁcacy and
safety outcomes estimated by the weighted ischemic stroke
equivalents in the RE-LY trial indicate that both dabigatran
110 mg bid and dabigatran 150 mg bid are superior to
warfarin when considering their integrated effects on major
ischemic and bleeding events. At a group level, each dabi-
gatran dose prevents about 1 more ischemic strokeequivalent (compared with warfarin) for every 100 patients
treated for a year. When comparing the 2 doses of dabiga-
tran, their net clinical beneﬁt is similar irrespective of
whether death is included in the calculation of net beneﬁt.
The results are also similar when net beneﬁt is examined
using unweighted composite outcomes that include various
combinations of major efﬁcacy and safety events.
The largest difference between the 2 dabigatran doses
was in their effects on major bleeding and on ischemic
stroke, with similar effects on the other events. The relative
reduction in ischemic stroke with dabigatran 150 mg bid
compared with 110 mg bid was large (31%; 95% CI: 12% to
46%) (1,2). Similarly the reduction in major extracranial
bleeding with dabigatran 110 mg compared with 150 mg
was substantial (12%; 95% CI: –2% to 25%) (3). Although
the weight of ischemic stroke in using ischemic stroke
equivalents was 1.40 times that of major extracranial
Table 3
Effect of Dabigatran 150 mg bid Compared With Dabigatran 110 mg bid on Mortality, Different Composites of Serious Thrombotic
and Bleeding Events, and Unweighted Net Clinical Beneﬁt
Dabigatran 110 mg
bid, n (Rate/100
Patient-Yrs)
Dabigatran 150 mg
bid, n (Rate/100
Patient-Yrs)
Warfarin,
n (Rate/100
Patient-Yrs)
Dabigatran 110 mg
Versus Warfarin,
HR (95% CI)
Dabigatran 150 mg
Versus Warfarin,
HR (95% CI)
Dabigatran 150 mg
Versus 110 mg bid,
HR (95% CI)
All-cause mortality 446 (3.75) 438 (3.64) 487 (4.13) 0.91 (0.80 to 1.03) 0.88 (0.77 to 1.00) 0.97 (0.85 to 1.11)
Cardiovascular mortality 289 (2.43) 274 (2.28) 317 (2.69) 0.90 (0.77 to 1.06) 0.85 (0.72 to 0.99) 0.94 (0.79 to 1.11)
Stroke or major bleed 474 (3.98) 486 (4.04) 536 (4.54) 0.87 (0.77 to 0.99) 0.89 (0.79 to 1.01) 1.02 (0.90 to 1.15)
Disabling stroke or life-
threatening bleed
220 (1.85) 220 (1.83) 268 (2.27) 0.81 (0.68 to 0.97) 0.80 (0.67 to 0.96) 0.88 (0.82 to 1.19)
Disabling stroke or life-
threatening bleed or death
598 (5.03) 579 (4.810) 656 (5.56) 0.90 (0.81 to 1.01) 0.86 (0.77 to 0.96) 0.96 (0.85 to 1.07)
Disabling stroke or life-
threatening bleed or
cardiovascular death
460 (3.87) 442 (3.67) 516 (4.38) 0.88 (0.78 to 1.00) 0.84 (0.74 to 0.95) 0.95 (0.83 to 1.08)
Stroke or myocardial infarction
or major bleed
548 (4.61) 548 (4.55) 594 (5.04) 0.91 (0.81 to 1.03) 0.91 (0.81 to 1.02) 0.99 (0.88 to 1.12)
Unweighted net clinical beneﬁt* 873 (7.34) 855 (7.11) 933 (7.91) 0.92 (0.84 to 1.01) 0.90 (0.82 to 0.99) 0.97 (0.88 to 1.07)
*Deﬁned as the composite outcome, stroke, systemic embolism, pulmonary embolism, myocardial infarction, death, or major bleeding.
CI ¼ conﬁdence interval; HR ¼ hazard ratio.
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907bleeding, the more than twice as many major bleeds as
ischemic strokes in RELY explains the similar effects of the
2 doses of dabigatran on ischemic stroke equivalents.
Various approaches have been used to assess the net clinical
beneﬁt of antithrombotic therapy. Hong and colleagues
weighted individual vascular outcomes according to their
impact on disability-adjusted life years using World Health
Organization Global Burden of Disease Project methodology
(11). Singer et al. (12) calculated the weighted net clinical
beneﬁt of warfarin compared with placebo or no warfarin for
stroke prevention in AF by assigning intracranial hemorrhage
a weight of 1.5 or 2.0 relative to ischemic stroke. The latter
approach reﬂects the greater importance of hemorrhagic
compared with ischemic stroke for patients, but is limited by
arbitrary assignment of weights and does not take into account
other events that are also important for patients (e.g., extra-
cranial bleeding, MI). Both Olesen et al. (13) and Banerjee et
al. (14) arbitrarily assigned hemorrhagic stroke a weight of 1.5
relative to ischemic stroke when calculating the net clinical
beneﬁt of various antithrombotic therapies for stroke
prevention in atrial ﬁbrillation. By disregarding extracranial
bleeding, both studies may have overestimated the beneﬁts of
dabigatran compared with warfarin in patients at high risk of
stroke who are also at high risk of bleeding. Building on the
methods by Singer et al. (12) and others (1,13,14), we have
taken into account all major cardiovascular events and have
used the adjusted hazard of death after each type of important
ischemic and bleeding events to determine their weight. We
believe that this novel approach has wider applicability to
evaluate the net beneﬁt of other treatments that require
physicians and patients to consider the tradeoff between
beneﬁts and harms.
The decision by the U.S. FDA to approve only the 150
mg bid dose of dabigatran was based on their assessment
that extracranial bleeding was relatively unimportant, espe-
cially compared with stroke (4). This view is also present inthe work of Singer et al. (12), who in their weighting of
events for net beneﬁt analysis in AF patients assigned
a weight of zero to extracranial bleeding. Challenging this
view, a large number of studies of patients receiving either
antiplatelet or anticoagulant therapy have found that patients
with bleeding have a signiﬁcant increase in major cardio-
vascular events and mortality compared with those who do
not experience an outcome event (15,16). Furthermore,
lower antithrombotic drug doses that are associated with
reduced bleeding have demonstrated improved efﬁcacy and
a reduction in mortality (17). We observed that the impact
on mortality of an extracranial bleed was equivalent to about
three-quarters of that of ischemic stroke. Adverse outcomes
after bleeding may be a direct effect of bleeding (e.g., shock,
exsanguination), an indirect effect related to hazard of blood
transfusion and risk of antithrombotic drug discontinuation,
or may be confounded by factors that are associated with
both bleeding and death (e.g., comorbidities, frailty).
The ﬁnding of a similar overall beneﬁt of dabigatran 110
mg bid and 150 mg bid over warfarin might be interpreted
as providing support for using any of the 2 dabigatran doses
for stroke prevention in AF. However, these results are
based on group comparisons and randomly assigned doses
and do not take into account individual patient character-
istics or preferences. The 2 dabigatran doses achieved their
beneﬁts relative to warfarin somewhat differently, the higher
dose of dabigatran by reducing ischemic stroke and the lower
dose by reducing bleeding. Although many patients appear
to place greater value on avoidance of stroke compared with
bleeding, and thus may be expected to prefer the higher dose
of dabigatran, this is not universal (18). Our subgroup
analyses also suggest that higher-risk patients, based on
higher CHADS2 or CHA2DS2VASc scores, had a larger
net beneﬁt with the lower dose of dabigatran and lower-risk
patients had a larger overall beneﬁt with the higher dose.
This supports the concept that the best balance between
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908beneﬁt and risk for individual patients may be obtained by
tailoring the dabigatran dose according to a patient’s risk of
stroke and bleeding.
Study limitations. First, we did not consider the impact of
outcomes on morbidity or quality-of-life measures in the RE-
LY trial because these data were not collected. In the
ACTIVE trial, estimates of net clinical beneﬁt of the
combination of aspirin and clopidogrel compared with aspirin
alone were similar irrespective of whether events were
weighted according to their impact on death alone or their
impact on disability and death (5), but we do not know
whether the results based on disability and death would also
be similar to those based on death in RE-LY. Second, we
weighted events according to their impact on death but did
not incorporate death in our primary analysis. We used this
approach because the 2 doses of dabigatran had a similar effect
on mortality and there is not a straightforward way to quan-
titatively weight death relative to any of the other outcomes.
We do, however, also report the results that were obtained
after incorporating death in our estimates of net clinical
beneﬁt, which produced similar results when comparing the
net beneﬁt of the 2 doses of dabigatran. Third, these are post
hoc analyses; before the start of the RE-LY trial we did not
anticipate formally evaluating the net clinical beneﬁt of the 2
doses of dabigatran.
Conclusions
On a group level both doses of dabigatran as compared with
warfarin have similar beneﬁts when considering a weighted
estimate including both efﬁcacy and safety. These data
support a role for both the 110 mg and the 150 mg dose of
dabigatran in clinical practice and the approach of tailoring
the dose based on individual patient characteristics.
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